Free Trial
→ Urgent: Invest In ‘Elon’s iPhone’ Before July 22nd (From StocksToTrade) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
$2.03
$2.21
$1.80
▼
$3.07
$22.06M0.1751,661 shs10,528 shs
FSDDF
FSD Pharma
$2.94
-5.5%		$3.37
$3.43
▼
$68.66
$22.29MN/A11,100 shs129,997 shs
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
$0.19
$0.17
$0.14
▼
$0.42
$5.86M0.519,406 shs5,100 shs
OPTH
Optimi Health
$4.02
$4.75
$4.00
▼
$6.40
$23.04MN/A44,528 shs21,409 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
0.00%-1.93%+2.01%-6.88%-13.98%
FSDDF
FSD Pharma
0.00%-14.53%-10.64%-11.18%-79.74%
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
0.00%+3.85%+11.18%+14.79%-39.03%
OPTH
Optimi Health
0.00%-10.47%-9.05%-12.99%+401,999,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
$2.03
$2.21
$1.80
▼
$3.07
$22.06M0.1751,661 shs10,528 shs
FSDDF
FSD Pharma
$2.94
-5.5%		$3.37
$3.43
▼
$68.66
$22.29MN/A11,100 shs129,997 shs
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
$0.19
$0.17
$0.14
▼
$0.42
$5.86M0.519,406 shs5,100 shs
OPTH
Optimi Health
$4.02
$4.75
$4.00
▼
$6.40
$23.04MN/A44,528 shs21,409 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
0.00%-1.93%+2.01%-6.88%-13.98%
FSDDF
FSD Pharma
0.00%-14.53%-10.64%-11.18%-79.74%
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
0.00%+3.85%+11.18%+14.79%-39.03%
OPTH
Optimi Health
0.00%-10.47%-9.05%-12.99%+401,999,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
2.00
Hold$14.50614.29% Upside
FSDDF
FSD Pharma
0.00
N/AN/AN/A
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
0.00
N/AN/AN/A
OPTH
Optimi Health
1.50
ReduceN/AN/A

Current Analyst Ratings Breakdown

Latest INBP, OPTH, FSDDF, and AYTU Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/6/2026
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D) ➝ Sell (D-)
10/5/2026
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
9/22/2026
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingPositive
9/22/2026
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D-) ➝ Sell (D)
8/27/2026
OPTH
Optimi Health
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/14/2026
OPTH
Optimi Health
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/13/2026
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
7/15/2026
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
(Data available from 10/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
$57.57M0.38N/AN/A$3.29 per share0.62
FSDDF
FSD Pharma
$70K318.36N/AN/AN/A∞
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
$43.87M0.13N/AN/A$0.57 per share0.33
OPTH
Optimi Health
$310K74.31N/AN/AN/A∞
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
-$14.25M-$1.66N/A14.50N/A-24.76%-56.54%-13.14%11/12/2026 (Estimated)
FSDDF
FSD Pharma
-$17.52M-$1.29N/AN/AN/AN/AN/AN/AN/A
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
-$2.84M-$0.10N/AN/AN/A-6.48%-14.78%-11.24%N/A
OPTH
Optimi Health
-$1.12M-$0.76N/AN/AN/AN/AN/AN/AN/A

Latest INBP, OPTH, FSDDF, and AYTU Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/25/2026Q4 2026
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
N/A-$0.04N/A-$0.04N/A$9.80 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
N/AN/AN/AN/AN/A
FSDDF
FSD Pharma
N/AN/AN/AN/AN/A
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
N/AN/AN/AN/AN/A
OPTH
Optimi Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
0.26
1.13
1.00
FSDDF
FSD Pharma
N/A
1.81
1.60
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
N/A
3.00
1.42
OPTH
Optimi Health
0.04
0.06
0.03

Institutional Ownership

CompanyInstitutional Ownership
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
33.49%
FSDDF
FSD Pharma
0.43%
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
25.25%
OPTH
Optimi Health
N/A

Insider Ownership

CompanyInsider Ownership
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
4.90%
FSDDF
FSD Pharma
N/A
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
67.40%
OPTH
Optimi Health
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Aytu BioPharma Inc. stock logo
AYTU
Aytu BioPharma
8310.87 million10.34 millionNot Optionable
FSDDF
FSD Pharma
107.58 millionN/ANot Optionable
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
15030.98 million10.10 millionNot Optionable
OPTH
Optimi Health
95.73 millionN/AN/A

Recent News About These Companies

Optimi Health to Present at the ThinkEquity Conference
October 7, 2026  |  financialpost.comF
Optimi Health to Present at the ThinkEquity Conference
October 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/07/3376495/0/en/optimi-health-to-present-at-the-thinkequity-conference.html
Optimi Health Corp. Appoints Melanie Pump to Board of Directors
September 29, 2026  |  quiverquant.comQ
Optimi Health Appoints Melanie Pump to Board of Directors
September 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/29/3370707/0/en/optimi-health-appoints-melanie-pump-to-board-of-directors.html
Optimi Health completes psilocybin batch for trial and Australia supply
September 23, 2026  |  streetinsider.comhttps://www.streetinsider.com/FDA/Optimi+Health+completes+psilocybin+batch+for+trial+and+Australia+supply/27094133.html
Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply
September 23, 2026  |  financialpost.comF
Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply
September 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/23/3367523/0/en/optimi-health-completes-psilocybin-production-for-health-canada-approved-phase-2-mdd-trial-and-commercial-trd-supply.html
Optimi Health Corp. Appoints Michael Blough as Chief Clinical Development Officer to Advance Psychedelic Clinical Trials
September 22, 2026  |  quiverquant.comQ
Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer
September 22, 2026  |  financialpost.comF
Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer
September 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/22/3366426/0/en/optimi-health-appoints-dr-michael-blough-as-chief-clinical-development-officer.html
Optimi Health plans Phase 3 MDMA-assisted therapy trial for PTSD
September 16, 2026  |  streetinsider.comhttps://www.streetinsider.com/FDA/Optimi+Health+plans+Phase+3+MDMA-assisted+therapy+trial+for+PTSD/27067803.html
Optimi Health Plans Phase 3 Trial Of MDMA-Assisted Therapy For PTSD
September 16, 2026  |  rttnews.comhttps://www.rttnews.com/3691602/optimi-health-plans-phase-3-trial-of-mdma-assisted-therapy-for-ptsd.aspx
Optimi Health Corp. Plans Health Canada-Authorized Phase 3 Trial of MDMA-Assisted Therapy for PTSD
September 16, 2026  |  quiverquant.comQ
Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder
September 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/16/3363147/0/en/optimi-health-expands-clinical-program-with-phase-3-trial-evaluating-mdma-assisted-therapy-for-post-traumatic-stress-disorder.html
Optimi Health Corp.: Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder
September 10, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-09/69546161-optimi-health-corp-optimi-health-to-initiate-phase-2-clinical-trial-evaluating-psilocybin-assisted-therapy-for-major-depressive-disorder-399.htm
Optimi Health To Initiate Phase 2 Psilocybin Trial For Major Depression
September 10, 2026  |  rttnews.comhttps://www.rttnews.com/3690048/optimi-health-to-initiate-phase-2-psilocybin-trial-for-major-depression.aspx
Optimi Health to Start Phase 2 Trial of Psilocybin-Assisted Therapy for Major Depressive Disorder in H1 2027
September 10, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/optimi-health-start-phase-2-145747194.html
Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder
September 10, 2026  |  financialpost.comF
Optimi Health Announces Health Canada-Authorized Phase 2 Trial of Natural Psilocybin for Major Depressive Disorder
September 10, 2026  |  quiverquant.comQ
Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder
September 10, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/10/3359517/0/en/optimi-health-to-initiate-phase-2-clinical-trial-evaluating-psilocybin-assisted-therapy-for-major-depressive-disorder.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aytu BioPharma stock logo

Aytu BioPharma NASDAQ:AYTU

$2.03 0.00 (0.00%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$2.08 +0.05 (+2.41%)
As of 10/9/2026 05:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

FSD Pharma OTCMKTS:FSDDF

$2.94 -0.17 (-5.47%)
As of 10/9/2026

FSD Pharma, Inc. is a specialty biotech pharmaceutical research and development company. It focuses on developing over time a robust pipeline of FDA-approved synthetic compounds targeting the endocannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of the skin, GI tract, and the musculoskeletal system. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz in 1994 and is headquartered in Cobourg, Canada.

Integrated BioPharma stock logo

Integrated BioPharma OTCMKTS:INBP

$0.19 0.00 (0.00%)
As of 10/9/2026 11:40 AM Eastern

Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.

Optimi Health NASDAQ:OPTH

$4.02 0.00 (0.00%)
As of 10/9/2026 03:59 PM Eastern

Optimi Health Corp. is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. Optimi Health Corp. is based in VANCOUVER, BC.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas